GIMEMA LAL1811: Phase II Study of Frontline Ponatinib + Steroids in Elderly or Unfit Patients With Ph+ ALL

Slideset - Ponatinib combined with steroids yielded a 90% complete hematologic response and reasonable tolerability profile at Week 24 in unfit and elderly patients with Philadelphia chromosome –positive ALL.

Source: Clinical Care Options Leukemia - December 20, 2017 Category: Hematology Source Type: research